43 results about "High dosage" patented technology

The invention provides a pharmaceutical composition for treating non-small cell lung cancer and application of the pharmaceutical composition. The pharmaceutical composition comprises gefitinib, erlotinib, afatinib, neratinib, osimertinib and the like which serve as active ingredients. The pharmaceutical composition disclosed by the invention can simultaneously contain various EGFR inhibitors as active ingredients, and the active ingredients are controlled at ultra-low dosage, so that the pharmaceutical composition not only can ensure the treatment effect, even the drug effect of the pharmaceutical composition is obviously superior to that of a high-dosage EGFR inhibitor independent administration group, but also can ensure the safety, and the pharmaceutical composition is suitable for clinical application. And after the active components are combined, a good synergistic effect is achieved, and more importantly, the occurrence of drug resistance can be remarkably reduced or even resisted. In a lung cancer cell culture experiment, the EGFR inhibitor independent administration group has a drug resistance phenomenon at the earliest 20 days, but the pharmaceutical composition group still has no drug resistance phenomenon after 160 days of administration.

A water remediation system and accompanying method includes remediation by reducing the concentration of nutrients in the water and dosing the water with metal ions. It has been found that through a combination of reducing nutrients present in the water and treating with metal ions, the requirement to treat with high chemical dosages is removed.

The invention discloses a screening and dosage determining method of a grape heat resistance inducer, and belongs to the technical field of plant stress resistance physiology and cultivation. The method comprises the following steps: soaking grape leaf wafers in inducers with different concentrations, and carrying out heat treatment under a plurality of temperature gradients; determining a chlorophyll OJIP rapid fluorescence parameter and constructing a heat resistance comprehensive index, and further calculating a normalized relative heat resistance improvement value; fitting a quantitative relation with the concentration by using a single-peak dose-effect model containing a high-dose inhibition item; statistical inference is carried out by adopting Bootstrap resampling, and a stable and effective recommended application concentration in a wide temperature range is finally determined by analyzing a common intersection or a statistical median of effective concentration intervals under multiple temperatures. The method realizes indoor rapid and quantitative screening, can realize quantitative comparison of induction intensity and dose sensitivity of different inducers under a unified evaluation system, and can be used for identifying heat resistance of grapes.

The invention discloses a hexapeptide LR6 with anti-inflammatory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide LR6 is LDAVDR, and the hexapeptide LR6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide LR6 is identified from spirulina platensis proteolysis liquid and has potential interaction with Keap1, an LPS-induced RAW264.7 cell test shows that TNF-alpha, IL-1beta and IL-10 can be remarkably inhibited by treatment of low-dose (200mM) and high-dose (400mM) hexapeptide LR6, the inhibition effect of the high-dose hexapeptide LR6 is superior to that of positive control dexamethasone, and the inhibition effect of the high-dose hexapeptide LR6 is superior to that of positive control dexamethasone. Compared with dexamethasone, the hexapeptide LR6 has a better anti-inflammatory effect and can be used for preparing anti-inflammatory drugs.

This invention discloses an ultrafine particle soil fluidized solidifier and an intelligent pile-forming process for in-situ pre-mixed fluidized solidified soil. The solidifier comprises cement, granulated blast furnace slag powder, and other main solidifying materials, along with an organic polymeric dispersant. Through the action of a low dosage of the organic polymeric dispersant, the plastic-to-fluid transition of the cohesive solidified soil is achieved, solving the technological challenges in preparing ultrafine particle fluidized solidified materials with high dosage, low moisture content, and high strength. An innovative airtight construction process is proposed. By introducing a pressurized airflow during mixing, the gas phase space of the ultrafine particle fluidized solidified material is increased, providing space for the growth of hydration product crystals and suppressing the strength-reducing effect of the organic polymeric dispersant on the solidified soil. This achieves rapid mixing of the solidifying material and the solidified soil, significantly improving the construction efficiency of in-situ soil solidification.

Aerosolization devices and procedures are described that improve air-jet dry powder inhaler (DPI) technologies and other types of inhalers, thereby optimizing aerosolization performance and expanding dosing capacity. One example device includes a variable-sized aerosolization chamber and an adjustment mechanism that allows the chamber size to be changed between activations. During use, the distance between the aerosolization chamber's air channel and the top of the powder bed remains virtually constant, even as the powder bed empties with each successive activation of the device.

An exhaust aftertreatment system comprises a pump; reagent dosing devices arranged in series with each other; and a controller. The controller comprises a dosing device diagnostic circuit configured to in a first stage measuring a first stage diagnostic indicating an amount of reagent dosed by all the reagent dosing devices, and comparing the measured first stage diagnostic with a nominal first stage diagnostic. If a deviation exceeds nominal performance then in a second stage of evaluation is triggered to identify a faulty reagent dosing device, wherein all the further reagent dosing devices are set to dose at a low quantity while simultaneously activating the first reagent dosing device to dose at two operating points, i.e. at a low dosing quantity and at medium or high dosing quantity and measuring a second stage diagnostic. The measured second stage diagnostic is compared with a nominal second stage diagnostic for determining if the first dosing device is operating correctly or faulty. In a third stage the first reagent dosing device is set to dose at a low quantity while simultaneously only one of the further reagent dosing devices is activated to dose at two operating points, i.e. at a low dosing quantity and at medium or high dosing quantity and a third stage diagnostic is measured and compared with a nominal second stage diagnostic for determining if said only one of said further reagent dosing devices is operating correctly or faulty.

This invention discloses an endothelin A receptor antagonist-albumin fusion protein and its application in preventing and treating hypotension during anesthesia induction. The fusion protein is formed by chemically coupling BQ-123 with human serum albumin (HSA). BQFu significantly enhances its antihypertensive effect by prolonging the half-life of BQ-123 and improving plasma stability. Experiments show that BQFu dose-dependently inhibits the decrease in mean arterial pressure (MAP) in a propofol-induced hypotension model, with a sustained and stable effect in the high-dose group (30 mpk), shortening the recovery time to 20.8 ± 10.5 min, while maintaining BQ-123 activity. This invention provides a long-acting and safe prevention and treatment strategy for hypotension during anesthesia induction.

The utility model discloses an antibacterial softener storage and use device with an accurate proportioning structure, and aims to provide the antibacterial softener storage and use device with the accurate proportioning structure, which has the advantages that the taking convenience is improved, and the dosage precision is high. The device comprises a base; the bracket is connected with the base; the storage box is connected with the support, and the storage box is connected with a switch assembly; the material receiving assembly is connected with the base, the material receiving assembly is provided with a quantifying cup, and a quantifying plate is movably connected with the base; and the ratio control assembly is connected with the support, the ratio control assembly is provided with a material return pipe, and the material return pipe is connected with the storage box and the quantitative cup. The device has the beneficial effects that various raw materials of the antibacterial softening and moistening agent can be quickly discharged in the device through the storage device, and meanwhile, the quantity can be accurately controlled; accurate control of the proportion is realized; the structural connection and operation stability is improved, and feeding and discharging are convenient to store; the operation efficiency is improved.

Provided are formulations and methods to treat ultra-potent synthetic opioid overdose with high dose Naloxone formulations comprising naloxone hydrochloride or a pharmaceutically acceptable salt thereof, one or more preservatives, one or more buffering agents, a tonicity modifier, and optionally a pH modifier.

This invention discloses a universal method and composition for solving the pilling problem in cold-formulated cosmetics. Adding an effective amount of glyceryl oleate, citrate / caprylic / capric triglyceride to a cosmetic composition containing a pilling-prone cold-formulated emulsifier can significantly reduce or eliminate pilling. This substance has been discovered for the first time to have a novel anti-pilling application, effective against pilling caused by the emulsifier's own characteristics, high dosage, electrolyte interference, or the addition of large molecules, and is universally applicable to different types of cold-formulated emulsifier systems. This invention is particularly suitable for systems using electrolyte-rich natural plant extracts as the aqueous phase, fundamentally solving the pilling problem and providing a reliable solution for preparing high-feel, all-natural cold-formulated cosmetics.

The present application relates to a kind of tetrahydroxy bile acid pharmaceutical composition and its preparation method and application.The present application provides a kind of pharmaceutical composition, it includes 100 weight parts of compound shown in formula I and 300~900 weight parts of saccharide.The present application also provides the use of the pharmaceutical composition in the preparation of drug for treating PFIC.The pharmaceutical composition of the present application can improve dose accuracy, solve the problem of poor taste of bile acid compound, easy to swallow, can improve the compliance of children drug.The pharmaceutical composition of the present application has good stability, easy to transport and store.In addition, the pharmaceutical composition of the present application realizes the stability of treatment effect under different doses, easy to accurately dose children according to body weight, while having good bioavailability, can realize good absorption and utilization in vivo.

The invention relates to application of autophagy in preparation of drugs or health food for improving fluorine-induced neurotoxicity from grape seed procyanidine. Rat and SH-SY5Y cell experiments are carried out, and the rat experiments prove that after intervention of different doses of GSPE, the SOD activity and the GSH content are improved, the MDA level is reduced, the antioxidant capacity of rats is recovered, autophagy is promoted, the filial generation learning and memory retention capacity is remarkably recovered, the autonomous activity capacity is recovered, anxiety behaviors are reduced, the occurrence and development processes of dental fluorosis are slowed down, and the occurrence and development of dental fluorosis are promoted. The change trends of different doses of GSPE present dose dependence, and the protection effect of a high-dose combined intervention group is most significant; in an SH-SY5Y cell experiment, the activity of the cells is improved through GSPE pretreatment, the expression quantity of cleave-caspase3 and cleaved-PARP is remarkably reduced, the autophagy process of the SH-SY5Y cells is promoted, and then the neurotoxicity caused by NaF is relieved. NaF is used as a representative, the prevention and treatment effects of GSPE on the fluorine-induced neurotoxicity are researched, and it is proved that GSPE can inhibit the NaF-induced neurotoxicity, so that the application of autophagy in preparation of drugs or health food for improving the fluorine-induced neurotoxicity from grape seed procyanidine is provided.

This invention relates to the field of concrete, and more particularly to a low-carbon concrete with a high dosage of industrial solid waste and its preparation method. By weight, its components include: cement: 170 parts; fly ash: 170 parts; fine aggregate: 600-800 parts; coarse aggregate: 1000 parts; water: 132 parts; polycarboxylate superplasticizer: 1 part; and modified material MIL53(Al-Fe)@SiO2: 1-5 parts. The invention prepares the MIL53(Al-Fe)@SiO2 modified material through in-situ conversion of fly ash and waste aluminum foil, and applies it to a 1:1 cement-fly ash high-dosage solid waste system. This method maintains high strength above 50 MPa and stable mechanical properties while significantly enhancing the density of the concrete, reducing chloride ion permeability from 0.34% to 0.18%, a reduction of 47.1%. This invention not only realizes the high-value utilization and low-carbon emission reduction of industrial solid waste, but also significantly improves the durability of concrete in harsh environments, and has significant environmental protection and engineering application value.

The application discloses application of bupropion hydrochloride tablets (75mg) in preparation of a medicine for treating stroke, and belongs to the technical field of new purposes of medicines. The core verifies the efficacy and safety of the medicine of the specification through systematic animal tests, aims at the problems of post-stroke neural function defect, motor dysfunction and insufficient neural plasticity, adopts a line plug method to prepare a rat focal cerebral ischemia (MCAO) model, sets multiple control tests, and explores the dosing effect of an equivalent dose of the bupropion hydrochloride tablets (75mg). The test results show that the medicine can significantly reduce the neural function defect score of the model animals, improve the motor coordination ability and the limb usage rate, increase the content of brain-derived neurotrophic factor (BDNF) in the brain, promote the repair of neural plasticity, and is safer than a high-dose scheme and has no obvious adverse reactions. Through complete animal test data, the application proves the effectiveness and safety of the bupropion hydrochloride tablets (75mg) in treating stroke, provides solid test basis for clinical conversion and application of the bupropion hydrochloride tablets (75mg), and has important medical application value.

The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.

The disclosure provides methods to reverse or regress fibrosis and / or liver cirrhosis in a subject in need thereof, using high-dose (pharmacologic) niacin, or a niacin analog thereof.

The invention provides an efficient oil-soluble paraffin remover and inhibitor as well as a preparation method and application thereof, and the efficient oil-soluble paraffin remover and inhibitor is mainly prepared from the following raw materials in parts by mass: 20-35 parts of oil-soluble polyether, 15-25 parts of a modified olefin copolymer, 5-12 parts of alkylbenzene sulfonate, 3-8 parts of fatty alcohol-polyoxyethylene ether, 8-15 parts of a cosolvent, 2-5 parts of a corrosion inhibitor and a proper amount of base oil. According to the efficient oil-soluble paraffin remover and inhibitor disclosed by the invention, a good paraffin remover and inhibitor effect can be ensured, and cost increase caused by too high dosage can be avoided; and the application range is wide, and the crude oil extraction requirements under different wax content and temperature conditions can be met.

The invention provides application of andrographolide in promoting calf growth and relieving weaning stress based on a microbial community regulation effect, and belongs to the technical field of animal feeding. The andrographolide (AG) can significantly improve the growth performance and the health level of the calves, relieve the weaning stress of the calves and improve the respiratory tract health of the calves by inhibiting inflammation and oxidative stress and systematically regulating and controlling microbial communities at multiple parts. Under the low-dosage feeding level, AG is more prone to optimizing rumen microflora, rumen is promoted to turn to an efficient propionic acid type fermentation mode, and sustainable benefits are achieved; and under a high dosage level, AG exerts a stronger anti-inflammatory and anti-oxidation effect to realize short-term benefit maximization. AG is added, so that the cross-site interaction between microbial communities in the digestive tract and the nasal cavity is enhanced, the colonization of various potential pathogens in the nasal cavity is remarkably inhibited, and the respiratory tract health of the calf is improved.

The present invention describes the combination of a 5HT3-antagonist with pramipexole to reduce or eliminate the adverse effects associated with the use of 5 pramipexole and to enable the use of high doses of pramipexole, useful for treating depressive disorders such as major depressive disorder 54 20 24 20 41 79 19 J un 2 02 4 J u n 2 0 2 4 A B S T R A C T 2 0 2 4 2 0 4 1 7 9 1 9

The present invention relates to a method of loading sotalol intravenously that starts with the highest approved doses, evaluates the QTc effects, and selects the highest does that is represented by a maximum serum drug concentration that does not excessively prolong the QTc interval on the electrocardiogram. The method further relates to down titration if needed.

The invention discloses a series of fatty acids for improving sleep and application thereof based on a dose classification effect mode. It is revealed for the first time that twelve single unsaturated fatty acids respectively follow three different dose response modes when improving sleep: a low-medium dose effective type (mode I), a medium-high dose effective type (mode II) and a full-dose progressive increase type (mode III). Particularly, the invention overcomes the negative cognitive prejudice on linoleic acid and arachidonic acid (belonging to mode I) in the prior art, and proves the sleep promoting effect of linoleic acid and arachidonic acid under a specific dosage. The invention also provides a composition containing the fatty acid (especially DHA and EPA in mode III), and a method for guiding product development based on the classification mode. The invention provides a core scientific basis for developing accurate and safe sleep-promoting medicines, health foods and food additives.

This invention relates to a purification agent and treatment method for ammonia-containing wastewater. The purification agent aims to address the problems of high dosage, high cost, and poor purification effect of existing chemical purification agents. The treatment method aims to solve the technical problems of poor treatment effect, long treatment time, high energy consumption, complex process, and high investment cost of existing ammonia-containing wastewater treatment methods. The purification agent consists of 30%-60% cyclohexanehexaphosphate, 1%-5% hexuronic acid, 1%-10% citric acid, and the balance being distilled water and / or demineralized water. The treatment method organically combines reagent reactions (neutralization, complexation, adsorption), precipitation separation, and fiber ball filtration to achieve wastewater purification. This purification method offers good purification effect, simple operation, low investment cost, and is less likely to generate hazardous waste.

The present invention relates inter alia to a drug dosing device comprising a dose scale having a plurality of different visual symbols representing a series of increasing dose unit settings in a number of consecutive dose unit settings defined by a dose increment between two consecutive dose unit settings. A first dose increment between two consecutive higher dose unit settings is selected so that dosing ranges of the two higher dose unit settings do not overlap, and a second dose increment between two consecutive lower dose unit settings is selected so that dosing ranges of the two lower dose unit settings do not overlap. The invention also relates to a dose scale.

The invention provides a biomarker for an intrathecal analgesic administration dosage conversion ratio and a determination method and system.The biomarker is selected from a # 9 region and a # 16 region of promoter regions of an ABCB1 gene and comprises a primer sequence at the 5'end of the # 9 region; a 3'end primer sequence of the # 9 region; a 5'end primer sequence of a # 16 region; and a 3'end primer sequence of the # 16 region. According to the invention, the methylation degree of two promoter regions of the ABCB1 gene is detected, and a proper dosage conversion ratio is judged when oral administration is converted into intrathecal administration, so that a rapid, effective and safe dosage scheme is provided for intrathecal analgesia patients; the individualized conversion proportion is selected according to the methylation degree, and the intrathecal dose titration speed is increased; the intrathecal analgesia patients are classified according to the methylation degree, and the corresponding dosage conversion proportion is selected; according to a methylation degree detection result, an oral administration dosage conversion ratio and an intrathecal administration dosage conversion ratio are classified, the intrathecal analgesic dosage is accurately guided, and the dosage titration efficiency is improved.

The present invention provides a high-dose oral pharmaceutical composition and high drug loading of isotretinoin with low fill-weight, and smaller size capsules, and methods of preparation and use thereof.

The present invention relates to regimens for the treatment of angiogenic eye diseases, such as nAMD, DR and DME, characterized by high doses of aflibercept over an extended period of time between administration.

Disclosed are high dose gastric retentive, extended-release lithium salt dosage forms suitable for once a day administration.

To provide an effective, long-term and safe pharmaceutical composition for use in a method of treating treatment-refractory or treatment-resistant depression in a patient diagnosed as having the depression.SOLUTION: A pharmaceutical composition for use in a method of treating treatment-resistant depression in a patient, wherein the pharmaceutical composition comprises esketamine and wherein the patient has not responded to at least two oral antidepressants in a current depressive episode, the pharmaceutical composition comprising: The method provides a pharmaceutical composition comprising: administering esketamine to the patient at least twice a week during a first induction phase of at least 4 weeks; evaluating the patient during the first induction phase; wherein the patient does not achieve a substantially complete response to esketamine; and re-starting the patient with the highest tolerated dose of esketamine in a second induction phase of at least 4 weeks.SELECTED DRAWING: None